RISPEFAR 4 MG

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

RISPERIDONE 4 MG

Available from:

PHARMALOGIC LTD

ATC code:

N05AX08

Pharmaceutical form:

FILM COATED TABLETS

Administration route:

PER OS

Manufactured by:

SPECIFAR S.A., GREECE

Therapeutic group:

RISPERIDONE

Therapeutic indications:

Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the treatment of psychotic manifestations of dementia. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

Authorization date:

2011-03-01